natgillin/translations-raw huggingface dataset:
The incidence of symptomatic LVD (congestive heart failure) was 1.3% in the group treated with Perjeta plus trastuzumab and docetaxel following FEC (this excludes a patient who experienced symptomatic LVD during FEC treatment prior to receiving Perjeta plus trastuzumab and docetaxel) and also 1.3% in the group treated with Perjeta in combination with TCH.
Incidencija simptomatske disfunkcije lijeve klijetke (kongestivnog zatajenja srca) iznosila je 1,3% u skupini liječenoj lijekom Perjeta plus trastuzumabom i docetakselom nakon terapije FEC-om (što ne uključuje bolesnika u kojeg je nastupila disfunkcija lijeve klijetke tijekom liječenja FEC-om prije nego što je primio lijek Perjeta plus trastuzumab i docetaksel) te također 1,3% u skupini liječenoj lijekom Perjeta u kombinaciji s
The incidence of symptoms observed in subjects over 60 years of age was generally lower as compared to the 18-60 years old population.
Incidencija simptoma opaženih u ispitanika starijih od 60 godina uglavnom je bila niža u usporedbi s populacijom u dobi od 18-60 godina.
The incidence of symptoms observed in subjects over 60 years of age was lower as compared to the 18-60 years old population.
Incidencija simptoma primijećenih u ispitanika starijih od 60 godina bila je niža u usporedbi s populacijom u dobi od 18- 60 godina.
The incidence of systemic ADRs after topical ophthalmic administration is lower than for systemic administration.
Incidencija sustavnih nuspojava nakon lokalne primjene u oko manja je nego pri sustavnoj primjeni.
The incidence of systemic ADRs after topical ophthalmic administration is lower than for systemic administration.
Učestalost sistemskih nuspojava na lijek nakon topikalne oftalmološke primjene niža je nego kod sistemske primjene.
The incidence of systemic adverse reactions after topical ophthalmic administration is lower than for systemic administration.
Incidencija sustavnih nuspojava nakon lokalne primjene lijeka u oko manja je nego pri sustavnoj primjeni.
The incidence of the adverse reactions below are expressed according to the following categories:
Incidencija nuspojava je izražena prema sljedećim kategorijama:
The incidence of the adverse reactions below are expressed according to the following categories:
Učestalost nuspojava u nastavku je izražena prema sljedećim kategorijama:
The incidence of the adverse reactions is expressed according to the following categories:
Incidencija nuspojava je izražena prema sljedećim kategorijama:
The incidence of the following adverse events (all grades): lethargy, stomatitis, neutropenic infection occurred at rates
Incidencija sljedećih nuspojava (svi stupnjevi): letargija, stomatitis, neutropenijska infekcija bila je
The incidence of the following adverse events (all grades): lethargy, stomatitis, neutropenic infection occurred at rates ≥ 10% higher in patients who were 65 years of age or older compared to younger patients.
Incidencija sljedećih nuspojava (svi stupnjevi): letargija, stomatitis, neutropenijska infekcija bila je ≥ 10% viša u bolesnika koji su imali 65 ili više godina u odnosu na mlađe bolesnike.
The incidence of the following grade ≥3 adverse reactions were higher in patients 65 years of age compared to younger patients; neutropenia based on laboratory abnormalities (86.3% versus 73.3%), clinical neutropenia (23.8% versus 16.8%) and febrile neutropenia (8.3% versus 6.1%) (see sections 4.2 and 4.4).
Incidencija sljedećih nuspojava stupnja ≥ 3 bila je veća u bolesnika u dobi od ≥ 65 godina u usporedbi s mlađim bolesnicima: neutropenija na temelju laboratorijskih odstupanja (86,3% u odnosu na 73,3%), klinička neutropenija (23,8% u odnosu na 16,8%) i febrilna neutropenija (8,3% u odnosu na 6,1%; vidjeti dijelove 4.2 i 4.4).
The incidence of the primary efficacy endpoint defined as first recurrence of AF or premature study drug discontinuation for intolerance or lack of efficacy at 12 months was 75% in the dronedarone group and 59% in the amiodarone group (hazard ratio = 1.59, log-rank p-value <0.0001).
Incidencija primarne mjere ishoda definirane kao prvi recidiv FA ili prijevremeni prekid primjene ispitivanog lijeka zbog nepodnošenja ili nedostatka djelotvornosti u 12. je mjesecu iznosila 75% u skupini koja je primala dronedaron i 59% u skupini koja je primala amiodaron (omjer rizika=1,59; log-rang p- vrijednost < 0,0001).
The incidence of the secondary safety outcome (major bleeding events) was lower in the rivaroxaban group (1.1% (26/2412)) than in the enoxaparin/VKA group (2.2% (52/2405)) with a hazard ratio 0.493 (95% CI: 0.308 - 0.789).
Incidencija sekundarnog ishoda sigurnosti (veća krvarenja) bila je niža u skupini na rivaroksabanu (1,1% (26/2412) nego u skupini na enoksaparinu/ antagonistu vitamina K (2,2% (52/2405)) uz omjer hazarda od 0,493 (95% CI: 0,308 – 0,789).
The incidence of these additional RAS mutations (KRAS exons 3, 4 and NRAS exons 2, 3, 4) in the wild-type KRAS (exon 2) population was approximately 10%.
Incidencija tih dodatnih RAS mutacija (egzoni 3, 4 gena KRAS i egzoni 2, 3 ,4 gena NRAS) u populaciji s divljim tipom gena KRAS (egzon 2) bila je približno 10%.
The incidence of these adverse reactions is related to the administered dose, the age of patients, and possibly inversely related to the age of patients at the onset of growth hormone deficiency.
Incidencija navedenih nuspojava povezana je s primijenjenom dozom, dobi bolesnika, te je vjerojatno obrnuto proporcionalna dobi bolesnika u vrijeme pojave deficita hormona rasta.
The incidence of these reactions in some clinical trials of Avastin is common (up to 5% in bevacizumab- treated patients).
Incidencija ovih reakcija je u pojedinim kliničkim ispitivanjima lijeka Avastin bila česta (do 5% u bolesnika liječenih bevacizumabom).
The incidence of thrombocytopenia was higher in the Gazyvaro plus chlorambucil arm (15%) compared to the rituximab plus chlorambucil arm especially during the first cycle.
Incidencija trombocitopenije bila je viša u skupini liječenoj lijekom Gazyvaro i klorambucilom (15%) nego u onoj liječenoj rituksimabom i klorambucilom, osobito tijekom prvog ciklusa.
The incidence of thrombocytopenia was low ( <1% , grade 3/4 ) and was not different between treatment arms.
Incidencija trombocitopenije bila je niska (< 1%, stupanj 3/4) i nije se razlikovala između dviju skupina.
The incidence of thrombocytopenia was low (<1%, grade 3/4%) and was not different between treatment arms.
Incidencija trombocitopenije bila je niska (< 1%, stupanj 3/4) i nije se razlikovala između dviju skupina.
The incidence of thrombocytopenia was lower in the Gazyvaro plus bendamustine (G+B) arm (15%) compared to the bendamustine (B) alone arm (24%).
Incidencija trombocitopenije bila je niža u skupini liječenoj lijekom Gazyvaro plus bendamustinom (G+B) (15%) nego u onoj koja je primala samo bendamustin (B) (24%).
The incidence of thyroid events was higher in patients with a medical history of thyroid disorders both in the LEMTRADA and interferon beta 1a (IFNB-1a) treatment groups.
Incidencija događaja štitnjače bila je veća u bolesnika s poremećajima štitnjače u povijesti bolesti u obje liječene skupine, onoj na lijeku LEMTRADA i onoj na interferonu beta 1a (IFNB-1a).
The incidence of treatment-induced/enhanced anti-rHuPH20 antibodies was 6% in the intravenous group compared with 9% in the subcutaneous group, and none of the patients who tested positive for anti-rHuPH20 antibodies tested positive for neutralizing antibodies.
Incidencija liječenjem izazvanog/pospješenog stvaranja antitijela na rHuPH20 iznosila je 6% u skupini liječenoj intravenskom formulacijom u usporedbi s 9% u skupini koja je primala supkutanu formulaciju, a nijedan od bolesnika s pozitivnim nalazom antitijela na rHuPH20 nije bio pozitivan na neutralizirajuća antitijela.
The incidence of withdrawal due to adverse events during the 30-week controlled trial was 6 % for prolonged-release exenatide treated patients, 5 % for immediate-release exenatide treated patients.
Incidencija prekida liječenja zbog nuspojava tijekom 30-tjednog kontroliranog ispitivanja bila je 6% za bolesnike liječene eksenatidom s produljenim oslobađanjem, a 5% za bolesnike liječene eksenatidom s trenutnim oslobađanjem.
The incidence of withdrawal due to adverse reactions was 7.8% for liraglutide­treated patients and 3.4% for comparator­treated patients in the long­term controlled trials (26 weeks or longer).
U dugotrajnim kontroliranim ispitivanjima (26 tjedana ili duže) incidencija prestanka primjene lijeka zbog nuspojava bila je 7,8% u bolesnika liječenih liraglutidom i 3,4% u bolesnika liječenih lijekom usporedbe.
The incidence of Xiapex-associated pruritus increased after more Xiapex injections in patients with Dupuytren’s contracture.
Incidencija pojave svrbeža povezanog s primjenom Xiapexa u bolesnika s Dupuytrenovom kontrakturom povećala se nakon više injekcija Xiapexa.
The incidence rate did not increase for malignancies overall, by major type (non-melanomatous skin cancer, solid tumors, and hematologic malignancies), or for individual tumor types in the double blind and open label period compared to the double-blind experience.
U usporedbi s dvostruko slijepom fazom, tijekom dvostruko slijepe i otvorene faze kliničkih ispitivanja nije se povećala ukupna učestalost zloćudnih bolesti kao ni učestalost glavnih (nemelanomski rak kože, solidni tumori i hematološke zloćudne bolesti) i individualnih vrsta tumora.
The incidence rate of new cases of infections in placebo-controlled clinical trials in rheumatoid arthritis was 1.03 per patient-year for all Cimzia-treated patients and 0.92 per patient-year for placebo-treated patients.
U placebom kontroliranim kliničkim istraživanjima reumatoidnog artritisa stopa incidencije novih slučajeva infekcija među bolesnicima liječenih Cimzijom bila je 1,03 bolesnik/godina, odnosno u skupini koja je primala placebo skupini 0,92 bolesnik/godina.
The incidence rate of observed malignancies was consistent with that expected in an age- and gender- matched rheumatoid arthritis population (see section 4.4).
Stopa incidencije opaženih zloćudnih bolesti bila je u skladu s očekivanom u populaciji bolesnika s reumatoidnim artritisom uravnoteženoj s obzirom na dob i spol (vidjeti dio 4.4).
The incidence rates for the primary safety outcome (major or clinically relevant non-major bleeding events) as well as the secondary safety outcome (major bleeding events) were similar for both treatment groups.
Stope incidencija za primarni ishod sigurnosti (veća ili klinički značajna manja krvarenja) kao i za sekundarni ishod sigurnosti (veća krvarenja) bile su slične u obje liječene grupe.
The incidence rates for the primary safety outcome (major or clinically relevant non-major bleeding events) as well as the secondary safety outcome (major bleeding events) were similar for both treatment groups.
Stope incidencije za primarni ishod sigurnosti (veća ili klinički značajna manja krvarenja) kao i za sekundarni ishod sigurnosti (veća krvarenja) bile su slične u obje liječene grupe.
The incidence rates for the primary safety outcome (major or clinically relevant non-major bleeding events) were slightly lower in the rivaroxaban treatment group (10.3% (249/2412)) than in the enoxaparin/VKA treatment group (11.4% (274/2405)).
Stope incidencija za primarni ishod sigurnosti (veća ili klinički značajna manja krvarenja) bile su lagano niže u skupini liječenoj rivaroksabanom (10,3% (249/2412)) nego u skupini liječenoj enoksaparinom/ antagonistom vitamina K (11,4% (274/2405)).
The incidence rates for the principal safety outcome (major and non-major clinically relevant bleeding events) were similar for both treatment groups (see Table 4).
Stopa incidencije za glavni ishod sigurnosti (veća i manja klinički značajna krvarenja) bila je slična za obje skupine bolesnika (vidjeti tablicu 4).
The incidence rates for the principal safety outcome (non-CABG TIMI major bleeding events) were higher in patients treated with Xarelto than in patients who received placebo (see Table 5).
Stope incidencije glavnog ishoda sigurnosti (ne-CABG TIMI veća krvarenja) bile su više u bolesnika liječenih lijekom Xarelto nego u bolesnika koji su primali placebo (vidjeti tablicu 5).
The incidence rates observed for first MACE+ were 1.2 and 1.1 events per 100 person-years for Eperzan versus all comparators, respectively.
Primijećena stopa incidencije za prvi MACE+ iznosila je 1,2 događaja na 100 bolesnik-godina za Eperzan odnosno 1,1 događaj na 100 bolesnik-godina za sve usporedne lijekove.
The incidence rates of key clinical fracture variables are presented in Table 4.
Stope incidencije ključnih varijabli kliničkih prijeloma prikazane su u Tablici 4.
The incidence rates of QTc 500 ms post baseline or QTc increase of 60 ms is 1.9%, 1.3%, 1.4% and 1.5%, for fesoterodine 4 mg, 8 mg, 12 mg and placebo, respectively.
Incidencija QTc ≥500 ms nakon početka liječenja ili povišenje QTc za ≥60 ms iznosila je 1,9% u skupini koja je primala 4 mg, 1,3% u skupini koja je primala 8 mg, 1,4% u skupini koja je primala 12 mg fesoterodina te 1,5% u skupini koja je primala placebo.
The incidence rates per 100 patient-years were 0.73 for non-melanomatous skin cancer, 0.59 for solid malignancies and 0.13 for hematologic malignancies.
Incidencija na 100 bolesnik-godina iznosila je 0,73 za nemelanomski rak kože, 0,59 za solidne malignome te 0,13 za hematološke malignome.
The incidences of adverse reactions experienced by 18 children and 97 adults treated with combination therapy were not significantly different between the two age groups except in the incidence of arthropathy (11.1% in children vs. none in adults, p=0.02).
Incidencije nuspojava koje su se pojavile u 18 djece i 97 odraslih osoba liječenih kombinacijskom terapijom nisu bile značajno različite između dvije dobne skupine osim incidencije artropatije (11,1% kod djece naspram niti jednog slučaja kod odraslih, p=0,02).
the incidences of all-cause mortality, major cardiovascular events, new
mora omogućiti usporedbu incidencije smrtnosti od svih uzroka,
the incidences of all-cause mortality, major cardiovascular events, new
usporedbu incidencije smrtnosti od svih uzroka, značajnih kardiovaskularnih
The incidences of Grade ≥3 neutropenia were higher in the high-trifluridine AUC group (47.8%) compared with the low-trifluridine AUC group (30.4%).
Incidencija neutropenije 3. stupnja ili više bila je veća u AUC skupini s visokim trifluridinom (47,8%) u usporedbi sa skupinom s niskim trifluridinom (30,4%).
The incidences of “Musculoskeletal and connective tissue disorders” and "Renal and urinary disorders" were lower during combination therapy than monotherapy, whereas the incidence of “Cardiac disorders" was higher during combination therapy than monotherapy.
Incidencije "poremećaja mišićno-koštanog sustava i vezivnog tkiva" te "poremećaja bubrega i mokraćnog sustava" bile su manje za vrijeme kombinacijske terapije nego za vrijeme monoterapije, dok je incidencija "srčanih poremećaja" bila veća za vrijeme kombinacijske terapije nego za vrijeme monoterapije.
The incident light dose is 20 J/cm2, delivered at an irradiance of 100 mW/cm2 to the tumour surface, implying an illumination time of approximately 200 seconds.
Doza upadne svjetlosti je 20 J/cm2, a dostavljeni intenzitet zračenja iznosi 100 mW/cm2 površine tumora, što znači da je vrijeme obasjavanja približno 200 sekundi.
The incident light dose is 20 J/cm2, delivered by the microlens fibre-optic in a circular field to the tumour surface at an irradiance of 100 mW/cm2, implying an illumination time of 200 seconds.
Doza upadne svjetlosti je 20 J/cm2, a dostavlja se fiberoskopom s mikrolećom na kružno područje površine tumora intenzitetom zračenja od 100 mW/cm2, što znači da vrijeme obasjavanja iznosi 200 sekundi.
The increase from baseline in lumbar spine and femoral neck BMD was 6.8 and 2.2, respectively in patients treated with Preotact.
Povećanje BMD u lumbalnoj kralježnici i femoralnom vratu femura u odnosu na početne vrijednosti bilo je 6,8%, odnosno 2,2% u bolesnica liječenih Preotactom.
The increase in 24-hour urine volume was dose dependent.
Povećanje volumena urina tijekom 24 sata ovisi o dozi.
The increase in 5-FU exposure in patients with mild renal impairment in this study together with the results of simulation in the population pharmacokinetic analysis suggest that a Teysuno dose of 25 mg/m2 twice daily in patients with mild renal impairment could achieve 5-FU plasma concentrations similar to those obtained in patients with normal renal function receiving 30 mg/m2 twice daily as monotherapy and also those with moderate renal impairment receiving 20 mg/m2 twice daily.
Porast izloženosti 5-FU-u u bolesnika sa blagim oštećenjem bubrega u ovoj studiji zajedno sa rezultatima simulacije u populacijskoj farmakokinetičkoj analizi, upućuje da doza lijeka Teysuno od 25 mg/m2 dva puta na dan u bolesnika s blagim oštećenjem bubrega može postići koncentraciju 5-FU-a u plazmi sličnu onoj postignutoj j u bolesnika sa normalnom bubrežnom funkcijom koji su uzimali 30 mg/m2 dva puta na dan kao monoterapiju kao i onoj postignutoj u bolesnika s umjerenim oštećenjem bubrežne funkcije koji su uzimali 20 mg/m2 dva puta na dan.
The increase in AUC∞, AUCt, and Cmax is of 111.88%, 114.06%, and 115.28% respectively.
Povećanje AUC∞, AUCt, i Cmax iznosi 111,88%, 114,06%, odnosno 115,28%.
The increase in fluticasone furoate systemic exposure in subjects with moderate hepatic impairment (fluticasone furoate/vilanterol 200/25 micrograms) was associated with an average 34% reduction in serum cortisol compared with healthy subjects.
Povećanje sistemske izloženosti flutikazonfuroatu u ispitanika s umjerenim oštećenjem jetre (flutikazonfuroat/vilanterol 200/25 mikrograma) bilo je povezano s prosječnim sniženjem serumskog kortizola za 34% u usporedbi sa zdravim ispitanicima.
The increase in mean AUC with increasing dose was linear and dose proportional in the range of 25–1,000 mg imatinib after oral administration.
Povećanje srednje AUC vrijednosti uz povećanje doze bilo je linearno i proporcionalno prema dozi u rasponu od 25 do 1000 mg imatiniba nakon peroralne primjene.
The increase in mean AUC with increasing dose was linear and dose proportional in the range of 25–1,000 mg imatinib after oral administration.
Povećanje srednje AUC vrijednosti uz povećanje doze bilo je linearno i proporcionalno prema dozi u rasponu od 25-1000 mg imatiniba nakon peroralne primjene.
The increase in mean AUC with increasing dose was linear and dose proportional in the range of 25–1,000 mg imatinib after oral administration.
Povećanje srednje vrijednostiAUC uz povećanje doze bilo je linearno i proporcionalno prema dozi u rasponu od 25-1000 mg imatiniba nakon peroralne primjene.
The increase in plasma concentrations was strongly correlated with an increase in terminal elimination half-lives.
Porast koncentracije plazme je usko povezan s povećanjem konačnog poluvremena eliminacije.
The increase in progestin exposure
Povećana izloženost progestinu može
The increase in steady state levels with the combined use of stiripentol, valproate, and clobazam is similar in adults and children, though inter-individual variability is marked.
Porast u koncentracijama u stanju dinamičke ravnoteže u kombiniranoj uporabi stiripentola, valproata i klobazama je sličan u djece i odraslih, iako su uočene interindividualne varijacije.
The increase in survival seen in the docetaxel weekly arm was not statistically significant compared to the mitoxantrone control arm.
Produljenje preživljenja u skupini koja je primala docetaksel tjedno nije bio statistički značajan u usporedbi sa kontrolnom skupinom koja je primala mitoksantron.
The increase in survival seen in the docetaxel weekly arm was not statistically significant compared to the mitoxantrone control arm.
Produljenje preživljenja u skupini koja je primala docetaksel tjedno nije bio statistički značajno u usporedbi s kontrolnom skupinom koja je primala mitoksantron.
The increase in tenofovir exposure (AUC and Cmax) was around 40-80% during co- treatment with Epclusa and tenofovir disoproxil fumarate/emtricitabine as part of various HIV regimens.
Povećanje izloženosti tenofiviru (AUC i Cmax) iznosilo je otprilike 40-80 % tijekom istodobnog liječenja lijekom Epclusa i tenofovirdisoproksilfumaratom/emtricitabinom u sklopu različitih režima za HIV.
The increase in vilanterol exposure was not associated with an increase in beta-adrenergic agonist related systemic effects on heart rate, blood potassium or QT interval (corrected using the Fridericia method).
Povećana izloženost vilanterolu nije bila povezana s povećanjem sistemskih učinaka beta-adrenergičkih agonista na frekvenciju otkucaja srca, razinu kalija u krvi niti QT-interval (korekcija metodom prema Fridericiji).
The increase in vilanterol exposure was not associated with an increase in beta2- agonist related systemic effects on heart rate, blood potassium or QTcF interval.
Povećanje izloženosti vilanterolu nije bilo povezano s povećanjem sistemskih učinaka beta2-agonista na srčani ritam, razinu kalija u krvi niti QTcF interval.
The increase is approximately 1.5 to 2-fold, corresponding to a 1.5-fold elevation of plasma AGP, to which imatinib binds strongly.
Povećanje je otprilike 1,5- do 2 puta veće, a odgovara 1,5 puta većem povećanju α-kiselog glikoproteina u plazmi, za koji se imatinib snažno veže.
The increase is approximately 1.5- to 2-fold, corresponding to a 1.5-fold elevation of plasma AGP, to which imatinib binds strongly.
Povećanje je od približno 1,5 do 2 puta što odgovara povećanju alfa- kiselog glikoproteina (AGP) u plazmi, proteina na koji se imatinib čvrsto veže, od 1,5 puta.
The increase of 25-O-
Povećanje 25-O
The increase of alkaline phosphatase by glucocorticoids could be related to enlargement of the liver (hepatomegaly) with increased serum hepatic enzymes.
Povišenje alkalne fosfataze glukokortikoidima može biti povezano s povećanjem jetre (hepatomegalijom) s povišenim enzimima jetre u serumu.
The increase of tipranavir
Bolesnici koji
The increase was statistically significant in this study (p=0.022).
Povećanje je bilo statistički značajno u ovom ispitivanju (p = 0,022).
The increase was statistically significant in this study (p=0.022).
Povećanje je bilo statistički značajno u ovom isptivanju (p = 0,022).
The increase was statistically significant in this study (p=0.022).
U ovom ispitivanju povećanje je bilo statistički značajno (p = 0,022).
The increased digoxin level may lessen over time as Pgp induction develops.
Povećana razina digoksina može
The increased dose interval for emtricitabine/tenofovir disoproxil in HIV-1 infected patients with moderate renal impairment is expected to result in higher peak plasma concentrations and lower Cmin levels as compared to patients with normal renal function.
Očekuje se da će povećani interval doziranja emtricitabina/tenofovirdizoproksila u bolesnika zaraženih virusom HIV-1 s umjerenim oštećenjem funkcije bubrega rezultirati višim vršnim koncentracijama u plazmi i nižim razinama Cmin u usporedbi s bolesnicima s normalnom bubrežnom funkcijom.
The increased dose interval for Truvada in HIV-1 infected patients with moderate renal impairment is expected to result in higher peak plasma concentrations and lower Cmin levels as compared to patients with normal renal function.
Očekuje se da će povećani interval između doza Truvade rezultirati u pacijenata zaraženih virusom HIV-1 s umjerenim oštećenjem funkcije bubrega višim vršnim koncentracijama u plazmi i nižim razinama Cmin u usporedbi s pacijentima s normalnom bubrežnom funkcijom.
The increased efavirenz concentrations observed following administration of STOCRIN with food may lead to an increase in frequency of adverse reactions (see sections 4.4 and 5.2).
Povišene koncentracije efavirenza zapažene nakon primjene lijeka STOCRIN uz hranu mogu povećati učestalost nuspojava (vidjeti dijelove 4.4 i 5.2).
The increased efavirenz concentrations observed following administration with food may lead to an increase in frequency of adverse reactions (see sections 4.4 and 5.2).
Povišene koncentracije efavirenza nakon njegove primjene s hranom mogu povećati učestalost nuspojava (vidjeti dijelove 4.4 i 5.2).